Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion type Assertion NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_head.
- NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion description "[Patients who met Adult Treatment Panel III MS criteria (n=29) presented lower plasma adiponectin concentrations (11.2 (7.4) vs. 19.6 (8.4) mg/l, P=0.004), lower EAT adiponectin mRNA (12.7 (3.0) vs. 15.1 (3.7) a.u., P=0.029) and similar SAT adiponectin mRNA levels (13.7 (4.2) vs. 15.6 (5.7) a.u., P=0.25) than those without MS. After adjusting for age, sex, CAD and heart failure, the association with MS remained statistically significant for plasma adiponectin (OR 0.862 (0.762-0.974)), was of borderline significance for EAT adiponectin mRNA (OR 0.796 (0.630-1.005)) and not significant for SAT adiponectin mRNA (OR 0.958 (0.818-1.122)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_provenance.
- NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion evidence source_evidence_literature NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_provenance.
- NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion SIO_000772 21330150 NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_provenance.
- NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion wasDerivedFrom befree-20140225 NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_provenance.
- NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_assertion wasGeneratedBy ECO_0000203 NP211922.RAEol9f0Wd64KHAsPwegmHfT8XlEgf8Riglw7YZHd6T6Y130_provenance.